Art. -Nr.: HY-N0510

Aristolochic acid A

(Synonyms: Aristolochic acid I; TR 1736)

11 Cited Publications

Kundenbewertung

Based on 11 publication(s) in Google Scholar

Aristolochic acid A (Aristolochic acid I; TR 1736) is the main component of plant extract Aristolochic acids, which are found in various herbal plants of genus Aristolochia and Asarum. Aristolochic acid A significantly reduces both activator protein 1 (AP-1) and NF-κB activities. Aristolochic acid A reduces BLCAP gene expression in human cell lines.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.91%
CAS. Nr.: 313-67-7
Formel: C₁₇H₁₁NO₇
Molecular Weight:341.27

Speicherung:

4°C, protect from light

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Aristolochic acid A Chemical Structure

CAS. Nr.: 313-67-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- Induced Disease Models
Chemical Information
Publications (11)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle NF-κB Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	EC₅₀	118.34 μM Compound: Aristolochic acid	Cytotoxicity in HEK293 cells assessed as reduction in cell survival incubated for 48 hrs by MTT assay Cytotoxicity in HEK293 cells assessed as reduction in cell survival incubated for 48 hrs by MTT assay	[PMID: 30108751]
Neutrophil	IC₅₀	>10 μg/mL Compound: 4	Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins	[PMID: 21353775]
Neutrophil	IC₅₀	>10 μg/mL Compound: 4	Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation after 5 mins Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation after 5 mins	[PMID: 21353775]
Panel NCI-60 (60 carcinoma cell lines)	GI₅₀	883 nM Compound: Aristolochic acid	Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program	[PMID: 15743190]

In Vitro

Aristolochic acid A (150, 200 μM, 24 hours) inhibits the cell viabilities of kidney cells HEK293 and HK-2^[1].
Aristolochic acid A (100, 200 μM, 24 hours) causes a concentration-dependent decrease in bladder cancer-associated protein (BLCAP) mRNA levels in kidney cells (HEK 293 and HK-2) , and bladder cancer cell line (HT-1376)^[1].
Aristolochic acid A (100, 200 μM, 24 hours) weakens the BLCAP protein signals in a dose-dependent manner in both HEK293 and HT-1376 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Kidney cells (HEK 293 and HK-2)
Concentration:

50, 100, 150, 200 μM
Incubation Time:

24 hours
Result:

The cell viabilities of HEK293 and HK-2 were lower than that of vehicle-treated cultures until 150 μM and 200 μM.

RT-PCR^[1]

Cell Line:

Kidney cells (HEK 293 and HK-2), and bladder cancer cell line (HT-1376)
Concentration:

100, 200 μM
Incubation Time:

24 hours
Result:

Down regulated the levels of BLCAP mRNA.

Western Blot Analysis^[1]

Cell Line:

HEK293 and HT-1376 cells
Concentration:

100, 200 μM
Incubation Time:

24 hours
Result:

Reduced the BLCAP protein expression in a dose-dependent manner.

Induced Disease Models

Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

Aristolochic acid A can be used to induce nephrotoxicity models. Pharmacokinetic studies show that in male C57BL/6 mice, the concentration of Aristolochic acid A in the kidneys is higher than in the liver 30 minutes after intraperitoneal administration (10 mg/kg). The plasma concentration of Aristolochic acid A also peaks approximately 30 minutes after administration^[2].

Induction of Nephrotoxicity ^[2]^[3]

Background

The pathogenesis of Aristolochic acid Anephropathy remains unclear. Research shows that Aristolochic acid A mainly damages renal tubular epithelial cells and renal tules, leading to interstitial fibrosis, thereby producing nephrotoxicity.

Specific Modeling Methods

Mice: C57BL/6J • 8 weeks of age
Administration: 10 mg/kg • i.p. • 3-5 days^[3]

Modeling Indicators

Pathology changs: H&E stain shows renal tissue structure is disordered, glomerular edema, pyknosis, and proximal tubule epithelial cell shedding
Biochemistry changes: Scr and blood urea nitrogen (BUN) contents increases

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 313-67-7
Appearance Solid
Molecular Weight 341.27
Formel C₁₇H₁₁NO₇
Color Light yellow to orange
SMILES

OC(C1=CC2=C(OCO2)C3=C4C(C(OC)=CC=C4)=CC([N+]([O-])=O)=C31)=O
Synonyms

Aristolochic acid I; TR 1736
Structure Classification
- Alkaloids
- Other Alkaloids
Initial Source
- Plants
- other families
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Publications (11)

All Bio/Physico-chemical AssayIn Vivo Efficacy StudyHistological Imaging/StainingIFCell Proliferation/Viability AssayWB

Sort by:

Journal Impact Factor

Nature

Bitter taste TAS2R14 activation by intracellular tastants and cholesterol. [Abstract]

2024 Jul;631(8020):459-466. PMID: 38776963

Aristolochic acid A purchased from MedChemExpress. Usage Cited in: Nature. 2024 Jul;631(8020):459-466. [Abstract]

FLIPR Ca2+ assay responses in wild-type (WT) TAS2R14 and mutants in pockets 1, 2 and 3, following Aristolochic acid A (150 μM) stimulation. The negative logarithmic half-maximal effective concentration (pEC50) and the maximum response (Emax) values were calculated from the concentration–response curves.
Cell Rep

Gut Bacteroides ovatus ameliorates renal fibrosis by promoting the production of HDCA through upregulation of Clostridium scindens. [Abstract]

2024 Oct 10;43(10):114830. PMID: 39392759
Life Sci

2026 Jun 27:402:124556. PMID: 42364692
Precis Clin Med

Dissection of cellular and molecular mechanisms of aristolochic acid-induced hepatotoxicity via single-cell transcriptomics. [Abstract]

2022 Sep 22;5(4):pbac023. PMID: 36349141

Aristolochic acid A purchased from MedChemExpress. Usage Cited in: Precis Clin Med. 2022 Sep 22;5(4):pbac023. [Abstract]

Aristolochic acid A (AAI, 2 mg/kg/day). Body weight of mice in Control, AAI-4w, and AAI-8w groups.

Aristolochic acid A purchased from MedChemExpress. Usage Cited in: Precis Clin Med. 2022 Sep 22;5(4):pbac023. [Abstract]

Aristolochic acid A (AAI, 2 mg/kg/day, 4 or 8 weeks). H&E staining showed pathological changes of mice livers after AAI treatment, scale bar = 100 μm.

Aristolochic acid A purchased from MedChemExpress. Usage Cited in: Precis Clin Med. 2022 Sep 22;5(4):pbac023. [Abstract]

Aristolochic acid A (AAI, 2 mg/kg/day, 4 or 8 weeks). Liver/body weight ratio after AAI treatment (n = 5, ***P < 0.001, ns = not significant). Effects of AAI on the levels of serum ALT and AST in the indicated groups (n = 5, *P < 0.05, **P < 0.01, ns = not significant).

Aristolochic acid A purchased from MedChemExpress. Usage Cited in: Precis Clin Med. 2022 Sep 22;5(4):pbac023. [Abstract]

Aristolochic acid A (AAI, 2 mg/kg/day, 4 or 8 weeks). IF staining of p-STAT3 (red) in the three groups, and the nuclei were stained by Hoechst (blue), scale bar = 50 µm.

Aristolochic acid A purchased from MedChemExpress. Usage Cited in: Precis Clin Med. 2022 Sep 22;5(4):pbac023. [Abstract]

Aristolochic acid A (AAI, 2 mg/kg/day, 4 or 8 weeks). IF staining of Bcl-2 (green) and Bax (Red) to detect endothelial cell apoptosis in the three groups, the nucleus was labelled by Hoechst (blue), scale bar = 40 µm.

Aristolochic acid A purchased from MedChemExpress. Usage Cited in: Precis Clin Med. 2022 Sep 22;5(4):pbac023. [Abstract]

Aristolochic acid A (AAI, 2 mg/kg/day, 4 or 8 weeks). Western blot was used to detect the expression of apoptotic signaling pathway-related markers cleaved-caspase 3, Bax, and Bcl-2 in liver tissues after AAI treatment.
Int J Mol Sci

Serum Amyloid A3 Promoter-Luciferase Reporter Mice Are Useful for Early Drug-Induced Nephrotoxicity Detection. [Abstract]

2024 May 8;25(10):5124. PMID: 38791162
Acupunct Herb Med

2025 July 31.
Toxicol Lett

Mitochondrial uptake of aristolactam I plays a critical role in its toxicity. [Abstract]

2024 Apr:394:76-91. PMID: 38428544
Front Genet

Integration of Transcriptomic and Metabolomic Data to Compare the Hepatotoxicity of Neonatal and Adult Mice Exposed to Aristolochic Acid I. [Abstract]

2022 Mar 25;13:840961. PMID: 35401701
Chin J Integr Med

Schisandra chinensis Oil Attenuates Aristolochic Acid I-Induced Nephrotoxicity in vivo and in vitro. [Abstract]

2022 Jul;28(7):603-611. PMID: 35391592
bioRxiv

2024 Apr 15.
Authorea

2023 Feb 17.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 16.67 mg/mL (48.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9302 mL

14.6512 mL

29.3023 mL

5 mM

0.5860 mL

2.9302 mL

5.8605 mL

10 mM

0.2930 mL

1.4651 mL

2.9302 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (6.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (287 KB)
SDS (643 KB)
- English - EN (643 KB)
- Français - FR (643 KB)
- Deutsch - DE (643 KB)
- Norwegian - NO (643 KB)
- Español - ES (643 KB)
- Swedish - SV (643 KB)
- Italian - IT (643 KB)
- Korean - KR (643 KB)
- Portuguese - PT (643 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Huang YT, et al. Aristolochic acid I interferes with the expression of BLCAP tumor suppressor gene in human cells. Toxicol Lett. 2018 Jul;291:129-137. [Content Brief]

[2]. Chenchen Feng, et al. Tanshinone I protects mice from aristolochic acid I-induced kidney injury by induction of CYP1A. Environ Toxicol Pharmacol. 2013 Nov;36(3):850-7. [Content Brief]

[3]. Youjia Zeng, et al. Autophagy inhibitors promoted aristolochic acid I induced renal tubular epithelial cell apoptosis via mitochondrial pathway but alleviated nonapoptotic cell death in mouse acute aritolochic acid nephropathy model. Apoptosis. 2014 Aug;19(8):1215-24. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9302 mL	14.6512 mL	29.3023 mL	73.2558 mL
	5 mM	0.5860 mL	2.9302 mL	5.8605 mL	14.6512 mL
	10 mM	0.2930 mL	1.4651 mL	2.9302 mL	7.3256 mL
	15 mM	0.1953 mL	0.9767 mL	1.9535 mL	4.8837 mL
	20 mM	0.1465 mL	0.7326 mL	1.4651 mL	3.6628 mL
	25 mM	0.1172 mL	0.5860 mL	1.1721 mL	2.9302 mL
	30 mM	0.0977 mL	0.4884 mL	0.9767 mL	2.4419 mL
	40 mM	0.0733 mL	0.3663 mL	0.7326 mL	1.8314 mL

Keywords

Aristolochic acid A

11 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Aristolochic acid A

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Alkaloids Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Off-patent Drug Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Aristolochic acid A

Alle NF-κB Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (11)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Aristolochic acid A Related Classifications

HY-N0510 Related Classifications